ストックスクリーナーアプリを入手
7.94
1.40%
0.11
アフターアワーズ：
7.95
0.010
+0.13%
前日終値:
$7.83
開ける：
$7.85
24時間の取引高:
236.35K
Relative Volume:
1.22
時価総額：
$428.17M
収益：
-
当期純損益:
$-35.10M
株価収益率:
-11.26
EPS:
-0.7051
ネットキャッシュフロー:
$-31.49M
1週間 パフォーマンス:
+15.91%
1か月 パフォーマンス:
+17.80%
6か月 パフォーマンス:
+15.74%
1年 パフォーマンス:
+16.08%
1日の値動き範囲:
$7.44
$8.00
1週間の範囲:
$6.825
$8.00
52週間の値動き範囲:
$5.245
$10.42
Diamedica Therapeutics Inc Stock (DMAC) Company Profile
名前
Diamedica Therapeutics Inc
セクター
電話
(763) 496-5454
住所
301 CARLSON PARKWAY, MINNEAPOLIS, MN
Compare DMAC vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DMAC
Diamedica Therapeutics Inc
|
7.94 | 428.17M | 0 | -35.10M | -31.49M | -0.7051 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-14 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-10-30 | 開始されました | TD Cowen | Buy |
| 2024-10-07 | 開始されました | H.C. Wainwright | Buy |
| 2024-04-24 | 再開されました | Craig Hallum | Buy |
| 2023-06-22 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-04-09 | 開始されました | Oppenheimer | Outperform |
| 2021-02-17 | 開始されました | ROTH Capital | Buy |
| 2020-10-30 | 開始されました | Guggenheim | Buy |
| 2020-07-08 | 開始されました | Maxim Group | Buy |
| 2019-04-30 | 開始されました | Dougherty & Company | Buy |
| 2019-03-05 | 開始されました | Lake Street | Buy |
すべてを表示
Diamedica Therapeutics Inc (DMAC) 最新ニュース
Avoiding Lag: Real-Time Signals in (DMAC) Movement - Stock Traders Daily
Wall Street Analysts Think DiaMedica Therapeutics (DMAC) Could Surge 129.97%: Read This Before Placing a Bet - Eastern Progress
DiaMedica Therapeutics Inc. (DMAC) Key Financial Ratios – Valuation, Profitability & More - Value Research
(DMAC) Risk Channels and Responsive Allocation - Stock Traders Daily
Price to earnings forward of DiaMedica Therapeutics Inc. – NASDAQ:DMAC - TradingView
(DMAC) Movement as an Input in Quant Signal Sets - Stock Traders Daily
DMAC Q2 2026 Earnings: Narrower-than-Expected Loss of $0.19 per ShareEPS Growth Rate - careplusvn.com
DiaMedica Therapeutics Inc. (DMAC) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Four New York investor talks are planned for September by DiaMedica - Stock Titan
Zomedica Corp. (ZOM) Peer Comparison – Compare with Others - Value Research
DiaMedica Therapeutics Inc. (DMAC) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
InMed Pharmaceuticals Inc. (INM) Peer Comparison – Compare with Others - Value Research
Understanding the Setup: (DMAC) and Scalable Risk - Stock Traders Daily
DiaMedica Therapeutics | 10-Q: Q2 2026 Earnings Report - Moomoo
DiaMedica (DMAC) Results Versus Estimates: EPS Lands Above Forecast; Share Response: The Market Price Advances 1.82% in the Current UpdateManagement Tone Analysis - vinanet.vn
DiaMedica Therapeutics Inc (DMAC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
META_TITLE_QUOTE - Yahoo Finance
DiaMedica's DM199: Multiple Catalysts AheadWill It Deliver? - RTTNews
DiaMedica (DMAC) Q2 2026 Earnings Call Transcript - AOL.com
DMAC Q2 2026 Earnings: Narrower-Than-Expected Loss Reflects Disciplined SpendingEBITDA Estimate Trend - Vinanet
DMAC Q2 2026 Earnings: Narrower-than-Expected Loss Highlights Cost Discipline as Pipeline AdvancesEarnings Expansion Phase - dars.gov.et
DiaMedica Therapeutics (DMAC) Slips 1.04% as Shares Consolidate Between $6.35 Support and $7.01 ResistanceBPI Bear Correction - vinanet.vn
DiaMedica Therapeutics (DMAC) Edges Lower as Shares Consolidate Within Established RangeWatchlist Stock Ideas - vinanet.vn
All You Need to Know About DiaMedica Therapeutics (DMAC) Rating Upgrade to Buy - Yahoo Finance
What is HC Wainwright's Estimate for DMAC Q3 Earnings? - MarketBeat
DiaMedica Therapeutics Inc. (DMAC) stock price, news, quote and history - Yahoo Finance UK
DiaMedica Therapeutics (DMAC) CEO receives 60,200 RSU award vesting over four years - Stock Titan
DiaMedica Expands Equity Incentive Pool With New S-8 Share Registration - The Globe and Mail
DiaMedica Therapeutics Inc (DMAC) (Q2 2026) Earnings Call Highlights: Promising Preeclampsia ... - Yahoo Finance
DiaMedica Therapeutics Inc (DMAC) (Q2 2026) Earnings Call Highli - GuruFocus
DiaMedica Therapeutics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
DiaMedica Therapeutics (DMAC) Advances Clinical Trials Amid High Price-to-Sales Valuation - GuruFocus
DiaMedica Therapeutics Q2 2026 Earnings Call Transcript - MarketBeat
DMAC Reiterated by HC Wainwright & Co. -- Price Target Maintained at $12 - GuruFocus
HC Wainwright Reaffirms Buy Rating for DiaMedica Therapeutics (NASDAQ:DMAC) - MarketBeat
DiaMedica Therapeutics Q2 Earnings Call Highlights - MarketBeat
Earnings call transcript: DiaMedica Q2 2026 loss matches forecast as trials advance - Investing.com
DiaMedica Therapeutics Reports Q2 2026 Form 10-Q Highlighting Clinical Trial Enrollment Challenges - Kalkine Media
DiaMedica Advances Key Phase 2 Programs and Extends Cash Runway Through 2027 - TipRanks
DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights - BioSpace
DiaMedica Therapeutics (DMAC) Reports Positive Interim Data, Mar - GuruFocus
DiaMedica Q2 net loss widens to $10.1M as DM199 shows clinical promise - scanx.trade
DiaMedica Therapeutics (NASDAQ:DMAC) Issues Quarterly Earnings Results - MarketBeat
DiaMedica Therapeutics reports Q2 net loss $10.1M, cash $43.5M; advances DM199 clinical programs - TradingView
DiaMedica reports $10.1 million Q2 loss as DM199 trials advance - Quiver Quantitative
DiaMedica Therapeutics (NASDAQ: DMAC) increases R&D spend and loss in Q2 2026 - Stock Titan
DiaMedica Therapeutics (DMAC) Slips to $6.75 as Biotech Stock Consolidates Between Key Support and ResistanceNAAIM Exposure - careplusvn.com
DiaMedica Therapeutics Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
DiaMedica Therapeutics Inc (DMAC) Stock News Today - TradingKey
(DMAC) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Press Release: DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights - 富途牛牛
Diamedica Therapeutics Inc (DMAC) 財務データ
収益
当期純利益
現金流量
EPS
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):